DE3782028D1 - Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen. - Google Patents

Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.

Info

Publication number
DE3782028D1
DE3782028D1 DE8787311078T DE3782028T DE3782028D1 DE 3782028 D1 DE3782028 D1 DE 3782028D1 DE 8787311078 T DE8787311078 T DE 8787311078T DE 3782028 T DE3782028 T DE 3782028T DE 3782028 D1 DE3782028 D1 DE 3782028D1
Authority
DE
Germany
Prior art keywords
awareness
giving
treatment
ketone derivatives
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787311078T
Other languages
English (en)
Other versions
DE3782028T2 (de
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630075A external-priority patent/GB8630075D0/en
Priority claimed from GB878726424A external-priority patent/GB8726424D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE3782028D1 publication Critical patent/DE3782028D1/de
Application granted granted Critical
Publication of DE3782028T2 publication Critical patent/DE3782028T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE8787311078T 1986-12-17 1987-12-16 Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen. Expired - Lifetime DE3782028T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868630075A GB8630075D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878726424A GB8726424D0 (en) 1987-11-11 1987-11-11 Medicaments

Publications (2)

Publication Number Publication Date
DE3782028D1 true DE3782028D1 (de) 1992-11-05
DE3782028T2 DE3782028T2 (de) 1993-02-18

Family

ID=26291706

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787311078T Expired - Lifetime DE3782028T2 (de) 1986-12-17 1987-12-16 Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.

Country Status (15)

Country Link
US (1) US4845115A (de)
EP (1) EP0275668B1 (de)
JP (1) JP2608078B2 (de)
KR (1) KR950013450B1 (de)
AU (1) AU618520B2 (de)
CY (1) CY1692A (de)
DE (1) DE3782028T2 (de)
DK (1) DK662687A (de)
ES (1) ES2052585T3 (de)
GR (1) GR3006255T3 (de)
HK (1) HK36693A (de)
IE (1) IE60991B1 (de)
IL (1) IL84845A0 (de)
NZ (1) NZ222950A (de)
PH (1) PH25025A (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
US5229407A (en) * 1988-09-01 1993-07-20 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
EP1022025A3 (de) * 1991-06-26 2002-06-05 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von Erbrechen, Übelkeit und anderen Störungen unter Verwendung von optisch reinem S(+)-ondansetron
JPH06509073A (ja) * 1991-06-26 1994-10-13 セプラコア，インコーポレーテッド 光学的に純粋なｓ（−）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
US5607938A (en) * 1993-03-08 1997-03-04 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating or preventing cerebrovascular infarction
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
ATE285235T1 (de) * 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
EP1181015A2 (de) 1999-03-01 2002-02-27 Sepracor Inc. Verfahren zur behandlung von apnoe und apnoe-erkrankungen mit optisch reinem r(+)ondansetron
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
AU579132B2 (en) * 1984-01-25 1988-11-17 Glaxo Group Limited Heterocyclic compounds
EP0191562B1 (de) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolonderivate
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions

Also Published As

Publication number Publication date
KR880007074A (ko) 1988-08-26
CY1692A (en) 1994-01-14
EP0275668A3 (en) 1989-10-11
KR950013450B1 (ko) 1995-11-08
IE60991B1 (en) 1994-09-07
PH25025A (en) 1991-01-28
HK36693A (en) 1993-04-23
AU8261487A (en) 1988-06-23
DK662687D0 (da) 1987-12-16
EP0275668A2 (de) 1988-07-27
IE873414L (en) 1988-06-17
NZ222950A (en) 1997-06-24
ES2052585T3 (es) 1994-07-16
EP0275668B1 (de) 1992-09-30
IL84845A0 (en) 1988-06-30
DK662687A (da) 1988-06-18
JP2608078B2 (ja) 1997-05-07
DE3782028T2 (de) 1993-02-18
GR3006255T3 (de) 1993-06-21
AU618520B2 (en) 1992-01-02
US4845115A (en) 1989-07-04
JPS63253083A (ja) 1988-10-20

Similar Documents

Publication Publication Date Title
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3688296D1 (de) Arzneimittel zur behandlung von erbrechen.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
NO165375C (no) Instrument for behandling av luftveishindringer.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
FI874671A0 (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE3770184D1 (de) Behandlung von gasstroemen.
DE3888056D1 (de) Oxadiazolyl-azabicycloheptane zur Behandlung von seniler Demenz.
DE3781574D1 (de) Calixaren-derivate und die verwendung dieser verbindungen zur sequestrierung von metallen.
DE3670956D1 (de) Behandlung von fluessigkeiten.
NO870409L (no) Fremgangsmaate for spaltning av 1-aminoindaner.
DE3481990D1 (de) Benzothiazol-2-sulfonamid-derivate, zur oertlichen behandlung von erhoehtem augeninnendruck.
DE68923219D1 (de) Behandlung von Abfällen.
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE3761377D1 (de) Verfahren zur aufarbeitung von 2-merkaptobenzthiazol enthaltenden teeren.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
NO872255D0 (no) Fremgangsmaate for dekaffinering av raakaffe.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE19675009I2 (de) Verfahren zur Herstellung von Hylan und Hylanverbindungen.
NO870113L (no) Behandling av brukte filtermedia.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition